FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early JulyCNBC • 03/06/23
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 03/05/23
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products AdministrationGlobeNewsWire • 02/27/23
Biogen shares fall on 4Q results but Canaccord analysts remain optimistic about Alzheimer's drugProactive Investors • 02/15/23
Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/15/23
Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug SalesInvestors Business Daily • 02/15/23
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionBusiness Wire • 02/06/23
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum DepressionGlobeNewsWire • 02/06/23
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines AgencyGlobeNewsWire • 01/26/23
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?The Motley Fool • 01/25/23